Document:

EX-10.181

 Exhibit 10.181

PLEDGE INDUCEMENT AGREEMENT

This PLEDGE INDUCEMENT AGREEMENT (this “Agreement”), dated as of August 4, 2005, is by and
between The Immune Response Corporation, a Delaware corporation (the “Company”), and Cheshire
Associates LLC, a Delaware limited liability company (“Cheshire”).

W I T N E S S E T H

WHEREAS, the Company proposes to raise gross proceeds of up to $2,000,000 by selling Secured
Convertible Debentures to Cornell Capital Partners, LP (“Cornell”) pursuant to a Securities
Purchase Agreement of even date herewith; and

WHEREAS, Cornell requires, as a condition to such transaction, that Cheshire pledge 6,000,000
shares of Company common stock, par value $.0025 per share, to Cornell, as partial security for the
Company’s obligations under the Secured Convertible Debentures; and

WHEREAS, the Company is willing to enter into this Agreement in order to induce such pledge;
and

WHEREAS, the parties contemplate that such pledge will be created via that certain Insider
Pledge and Escrow Agreement, dated of even date herewith, by and among the Company, Cheshire,
Cornell and David Gonzalez, Esq. (the “Insider Pledge and Escrow Agreement”); and

WHEREAS, pursuant to this Agreement and the Insider Pledge and Escrow Agreement, Cheshire
shall pledge 6,000,000 shares of Company common stock to Cornell as partial security for the
Company obligations under one or more Secured Convertible Debentures to be issued today and/or
hereafter by the Company to Cornell, with an aggregate principal amount of up to $2,000,000, in
consideration of the Company’s agreement herein to issue a formula-determined number of 5-year
Company common stock warrants to Cheshire and further subject to the terms set forth herein.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and promises
contained herein, and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties agree as follows:

1. Cheshire shall execute, deliver and perform the Insider Pledge and Escrow Agreement, including
delivering to the escrow agent thereunder a share certificate representing 6,000,000 shares of
Company common stock and a stock power, duly executed in blank by Cheshire and with Medallion
guaranty stamp affixed.

2. The Company and Cheshire shall thereupon execute and deliver the Warrant Agreement, in the form
attached hereto as Exhibit A. The initial exercise price under the Warrant Agreement shall be 100%
of the closing sale price of the Company common stock on the Nasdaq SmallCap Market on the initial
closing date of the Securities Purchase Agreement

3. It is understood that pursuant to Section 4(b) of the Insider Pledge and Escrow Agreement,
Cornell will release the pledged Cheshire shares when and if the Company obtains stockholder
approval for issuance of all shares called for by the Company’s various agreements with Cornell,
and the Company has entered into a Pledge and Escrow Agreement with Cornell, of like tenor
as the Pledge and Escrow Agreement dated today between the Company and Cornell, but this time
pledging under such future Pledge and Escrow Agreement an additional 9,326,000 shares of Company
common stock, and no “Event of Default” (within the meaning of the Insider Pledge and
Escrow Agreement) shall have been deemed to have occurred. The Company agrees to use its best
efforts to:

(a) expeditiously seek and obtain such stockholder approval;

	 	(b)	 	expeditiously thereafter enter into such future Pledge and
Escrow Agreement and pledge such additional 9,326,000 shares to Cornell; and

(c) avoid the occurrence of an Event of Default.

4. Miscellaneous.

4.1 Waivers and Amendments. This Agreement or any provisions hereof may be changed,
waived, discharged or terminated only by a statement in writing signed by the Company and by
Cheshire. This Agreement represents the entire agreement of the Company and Cheshire with regard
to the subject matter hereof, and it supersedes all prior or contemporaneous discussions,
negotiations, commitments and agreements with regard to such subject matter.

4.2 Governing Law. This Agreement shall be governed by and construed and enforced in
accordance with the laws of the State of New York.

4.3 Notices. All notices and other communications hereunder shall be in writing and
shall be deemed to have been given when delivered by hand or by facsimile transmission, or upon
receipt when mailed by registered or certified mail (return receipt requested), postage prepaid, to
the parties at the following addresses (or at such other address for a party as shall be specified
by like notice):

(i) If to the Company:

The Immune Response Corporation

5931 Darwin Court

Carlsbad, CA 92008

Attention: President

Facsimile: (760) 431-8636

With a copy (which copy shall not constitute notice) to:

Heller Ehrman LLP

4350 La Jolla Village Drive, 7th Floor

San Diego, CA 92122

Attention: Hayden Trubitt, Esq.

Facsimile: (858) 587-5903

(ii) If to Cheshire:

Cheshire Associates LLC

535 Madison Avenue

New York, NY 10022

Attention: Kevin Kimberlin and Bruno Lerer, Esq.

Facsimile: (212) 486-7392

With a copy (which copy shall not constitute notice) to:

Kirkpatrick & Lockhart LLP

1251 Avenue of the Americas, 45th Floor

New York, NY 10020-1104

Attention: Stephen R. Connoni, Esq./Sandip Kakar, Esq.

Facsimile: (212) 536-3901

4.4 Headings. The headings in this Agreement are for convenience of reference only,
and shall not limit or otherwise affect the terms hereof.

4.5 Successors. All the covenants and provisions of this Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and permitted
assigns and transferees.

4.6 Severability. If any provision of this Agreement shall be held to be invalid and
unenforceable, such invalidity or unenforceability shall not affect any other provision of this
Agreement.

1

IN WITNESS WHEREOF, the undersigned have caused this Pledge Inducement Agreement to be
executed as of the date first written above.

THE IMMUNE RESPONSE CORPORATION

By:

Name:

Title:

CHESHIRE ASSOCIATES LLC

By:

Name:

Title:

2

EXHIBIT A

FORM OF WARRANT AGREEMENT

3EX-10.182

 Exhibit 10.182

WARRANT AGREEMENT

WARRANT AGREEMENT (this “Agreement”), dated as of August 4, 2005 by and between The Immune
Response Corporation, a Delaware corporation (the “Company”), and Cheshire Associates LLC, a
Delaware limited liability company (the “Warrant Holder”).

W I T N E S S E T H

WHEREAS, the parties have entered into that certain Pledge Inducement Agreement dated as of
August 4, 2005 (the “Pledge Inducement Agreement”); and

WHEREAS, the parties and others have entered into that certain Insider Pledge and Escrow
Agreement, dated as of August 4, 2005, by and between the Company, the Warrant Holder, Cornell
Capital Partners, LP and David Gonzalez, Esq. (the “Insider Pledge and Escrow Agreement”); and

WHEREAS, pursuant to the Pledge Inducement Agreement and the Insider Pledge and Escrow
Agreement, the Warrant Holder has agreed to pledge 6,000,000 shares of Company common stock, par
value $.0025 per share (“Common Stock”) to Cornell Capital Partners, LP as partial security for the
Company obligations under one or more Secured Convertible Debentures to be issued today and/or
hereafter by the Company to Cornell Capital Partners, LP, with an aggregate principal amount of up
to $2,000,000, and the Company has accordingly agreed to issue to the Warrant Holder warrants (the
“Warrants”) to purchase shares of the Company’s common stock, subject to the terms set forth
herein.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and promises
contained herein, and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties agree as follows:

1. Warrants. The Company hereby grants to the Warrant Holder, subject to the terms set
forth herein, the right to purchase from the Company at any time and from time to time after the
date hereof until 5:00 p.m., New York City local time, on August 4, 2010 (the “Expiration Date”),
that number of fully paid and non-assessable shares of Common Stock, subject to adjustment pursuant
to Section 3 hereof (the “Shares”), which number of Shares equals 2,000 times the number of days
any of the Warrant Holder’s shares remain in pledge under the Insider Pledge and Escrow Agreement.
For purposes of this Agreement, the “Exercise Price” shall initially be $0.78, subject to any
adjustments pursuant to Section 3 hereof.

2. Exercise of Warrants.

2.1 Exercise. The Warrants may be exercised by the Warrant Holder, in whole or in
part, by delivering the Notice of Exercise purchase form, attached as Exhibit A hereto,
duly executed by the Warrant Holder to the Company at its principal office, or at such other office
as the Company may designate, accompanied by payment, in cash or by wire transfer or check payable
to the order of the Company, of the amount obtained by multiplying the number of Shares designated
in the Notice of Exercise by the Exercise Price (the “Purchase Price”). The Purchase Price may also
be paid, in whole or in part, by delivery of such purchase form and of shares of Common Stock owned
by the Warrant Holder having a Fair Market Value (as defined in Section 2.3 hereof) on the last
trading day ending the day immediately preceding the Exercise Date (as defined below) equal to the
portion of the Purchase Price being paid in such shares. In addition, the Warrants may be
exercised, pursuant to a cashless exercise, by providing irrevocable instructions to the Company,
through delivery of the aforesaid purchase form with an appropriate reference to this Section 2.1
to issue the number of shares of the Common Stock equal to the product of (a) the number of shares
as to which the Warrants are being exercised multiplied by (b) a fraction, the numerator of which
is the Fair Market Value of a share of the Common Stock on the last business day preceding the
Exercise Date less the Exercise Price therefore and the denominator of which is such Fair Market
Value. For purposes hereof, “Exercise Date” shall mean the date on which all deliveries required to
be made to the Company upon exercise of Warrants pursuant to this Section 2.1 shall have been made.

2.2 Issuance of Certificates. As soon as practicable after the exercise of the
Warrants (in whole or in part) in accordance with Section 2.1 hereof, the Company, at its expense,
shall cause to be issued in the name of and delivered to the Warrant Holder (i) a certificate or
certificates for the number of fully paid and non-assessable Shares to which the Warrant Holder
shall be entitled upon such exercise and (if applicable) (ii) a new warrant agreement of like tenor
to purchase all of the Shares that may be purchased pursuant to the portion, if any, of the
Warrants not exercised by the Warrant Holder. The Warrant Holder shall for all purposes be deemed
to have become the holder of record of such Shares on the date on which the Notice of Exercise and
payment of the Purchase Price in accordance with Section 2.1 hereof were delivered and made,
respectively, irrespective of the date of delivery of such certificate or certificates, except that
if the date of such delivery, notice and payment is a date when the stock transfer books of the
Company are closed, such person shall be deemed to have become the holder of record of such Shares
at the close of business on the next succeeding date on which the stock transfer books are open.

2.3 Fair Market Value. The “Fair Market Value” of a share of Common Stock on any day
means: (a) if the principal market for the Common Stock is The Nasdaq Stock Market or any national
securities exchange, the last sales price of the Common Stock on such day as reported by such
exchange or market, or on a consolidated tape reflecting transactions on such exchange or market,
or (b) if the principal market for the Common Stock is not a national securities exchange or The
Nasdaq Stock Market and the Common Stock is quoted on the National Association of Securities
Dealers Automated Quotations System, the mean between the closing bid and the closing asked prices
for the Common Stock on such day as quoted on such System, or (c) if the Common Stock is not quoted
on the National Association of Securities Dealers Automated Quotations System, the mean between the
highest bid and lowest asked prices for the Common Stock on such day as reported by Pink Sheets
LLC; provided, however, that if none of (a), (b) or (c) above is applicable, or if
no trades have been made or no quotes are available for such day, the Fair Market Value of the
Common Stock shall be reasonably determined, in good faith, by the Board of Directors of the
Company (the “Board of Directors”).

3. Adjustments.

3.1 Stock Splits, Stock Dividends and Combinations. If the Company at any time
subdivides the outstanding shares of the Common Stock or issues a stock dividend (in Common Stock)
on the outstanding shares of the Common Stock, the Exercise Price in effect immediately prior to
such subdivision or the issuance of such stock dividend shall be proportionately decreased, and the
number of Shares subject hereto shall be proportionately increased, and if the Company at any time
combines (by reverse stock split or otherwise) the outstanding shares of Common Stock, the Exercise
Price in effect immediately prior to such combination shall be proportionately increased, and the
number of Shares subject hereto shall be proportionately decreased, effective at the close of
business on the date of such subdivision, stock dividend or combination, as the case may be.

3.2 Merger or Consolidation. In the case of any consolidation of the Company with, or
merger of the Company with or into another entity (other than a consolidation or merger which does
not result in any reclassification or change of the outstanding capital stock of the Company), the
entity formed by such consolidation or merger shall execute and deliver to the Warrant Holder a
supplemental warrant agreement providing that the Warrant Holder of the Warrants then outstanding
or to be outstanding shall have the right thereafter (until the expiration of such Warrants) to
receive, upon exercise of such Warrants, the kind and amount of shares of capital stock and other
securities and property receivable upon such consolidation or merger by a holder of the number of
Shares for which such Warrants might have been exercised immediately prior to such consolidation or
merger. Such supplemental warrant agreement shall contain provisions which shall be identical to
the adjustments provided in Section 3.1 hereof and to the provisions of Section 10 hereof. This
Section 3.2 shall similarly apply to successive consolidations or mergers.

3.3 The Exercise Price shall also be subject to adjustment as follows:

(1) Special Definitions. For purposes of this Section 3.3, the following definitions
shall apply:

(A) “Options” shall mean rights, options or warrants to subscribe for, purchase or otherwise
acquire Common Stock or Convertible Securities.

(B) “Original Issue Date” shall mean the date of this Agreement.

(C) “Convertible Securities” shall mean any evidence of indebtedness, shares of capital stock
(other than Common Stock) or other securities convertible into or exchangeable for Common Stock.

(D) “Additional Shares of Common Stock” shall mean all shares of Common Stock issued by the
Company on or after the Original Issue Date, other than shares of Common Stock issued at any time:

(i) pursuant to the exercise of options, warrants or other Common Stock purchase rights issued
(or to be issued) to employees, officers or directors of, or consultants or advisors to, or any
strategic ally of, the Company pursuant to any stock purchase or stock option plan or other
arrangement approved by the Board of Directors;

(ii) pursuant to the exercise of options, warrants or Convertible Securities outstanding as of
the Original Issue Date;

(iii) in connection with the acquisition of all or part of another entity by stock
acquisition, merger, consolidation or other reorganization, or by the purchase of all or part of
the assets of such other entity (including securities issued to persons formerly employed by such
other entity and subsequently hired by the Company and to any brokers or finders in connection
therewith) where the Company or its stockholders own more than fifty (50%) percent of the voting
power of the acquired, surviving, combined or successor company; or

(iv) coming within the definition of Excluded Securities in the Warrant issued this day by the
Company to Cornell Capital Partners, LP.

(2) Issuance of Options and Convertible Securities. In the event the Company at any
time or from time to time after the Original Issue Date shall issue any Options (other than any
additional warrants issued to the Warrant Holder or any affiliate thereof in accordance with the
terms and provisions of the Note Purchase Agreement) or Convertible Securities without
consideration or for a consideration per share less than the then-applicable Exercise Price, then
and in such event, such Exercise Price shall be reduced, concurrently with such issue, to a price
(calculated to the nearest cent) determined by multiplying the then-applicable Exercise Price by a
fraction, (i) the numerator of which shall be the number of shares of Common Stock issued and
outstanding (on a fully-diluted basis) immediately prior to such issuance plus the quotient
obtained by dividing (x) the aggregate consideration received or to be received by the Company for
the total number of Additional Shares of Common Stock issuable upon the exercise, conversion or
exchange of such Options or Convertible Securities by (y) the Exercise Price, and (ii) the
denominator of which shall be the number of shares of Common Stock issued and outstanding (on a
fully-diluted basis) immediately prior to such issuance plus the number of Additional Shares of
Common Stock issuable upon the exercise, conversion or exchange of such Options or Convertible
Securities. Upon each such adjustment of the then-applicable Exercise Price pursuant to the
provisions of this Section 3.3(2), the number of Warrant Shares purchasable upon the exercise of
each Warrant shall be adjusted to the nearest full amount by multiplying a number equal to the
Exercise Price in effect immediately prior to such adjustment by the number of Warrant Shares
purchasable upon the exercise of each Warrant immediately prior to such adjustment and dividing the
product so obtained by the adjusted Exercise Price.

(3) Adjustment of Exercise Price Upon Issuance of Additional Shares of Common Stock.
In the event the Company, after the Original Issue Date, shall issue Additional Shares of Common
Stock without consideration or for a consideration per share less than the then-applicable Exercise
Price, then and in such event, such Exercise Price shall be reduced, concurrently with such issue,
to a price (calculated to the nearest cent) determined by multiplying the then-applicable Exercise
Price by a fraction, (i) the numerator of which shall be the number of shares of Common Stock
issued and outstanding (on a fully-diluted basis) immediately prior to such issuance plus the
quotient obtained by dividing (x) the aggregate consideration received by the Company for the total
number of Additional Shares of Common Stock so issued by (y) the Exercise Price, and (ii) the
denominator of which shall be the number of shares of Common Stock issued and outstanding (on a
fully-diluted basis) immediately prior to such issuance plus the number of Additional Shares of
Common Stock so issued. Upon each such adjustment of the then-applicable Exercise Price pursuant to
the provisions of this Section 3.3(3), the number of Warrant Shares purchasable upon the exercise
of each Warrant shall be adjusted to the nearest full amount by multiplying a number equal to the
Exercise Price in effect immediately prior to such adjustment by the number of Warrant Shares
purchasable upon the exercise of each Warrant immediately prior to such adjustment and dividing the
product so obtained by the adjusted Exercise Price.

(4) Determination of Consideration. For purposes of this Section 3, the consideration
received by the Company for the issue of any Additional Shares of Common Stock shall be computed as
follows:

(A) Cash and Property. Such consideration shall:

(i) insofar as it consists of cash, be computed at the net amount of cash received by the
Company excluding expenses, discounts and commissions payable by the Company in connection with
such issuance or sale and amounts paid or payable for accrued interest.

(ii) insofar as it consists of property other than cash, be computed at the fair value thereof
at the time of such issue, as reasonably determined in good faith by the Board of Directors net of
expenses as set forth in clause (i) above; and

(iii) in the event Additional Shares of Common Stock are issued together with other shares or
securities or other assets of the Company for consideration that covers both cash and property
other than cash, the proportion of such consideration so received, computed as provided in clauses
(i) and (ii) above, shall be as reasonably determined in good faith by the Board of Directors.

(B) Options and Convertible Securities. The consideration per share received by the Company
for the issuance of Options or Convertible Securities pursuant to Section 3.3(2) shall be
determined by dividing:

(i) the total amount, received by the Company as consideration for the issuance of such
Options or Convertible Securities, plus the minimum aggregate amount of additional consideration
payable to the Company upon the exercise of such Options or the conversion or exchange of such
Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such
Options for Convertible Securities and the conversion or exchange of such Convertible Securities
(subject to any adjustments in the exercise price thereof), by

(ii) the number of shares of Common Stock issuable upon the exercise of such Options or the
conversion or exchange of such Convertible Securities or, in the case of Options for Convertible
Securities, the exercise of such Options for Convertible Securities and the conversion or exchange
of such Convertible Securities.

3.4 Certificate as to Adjustments. Upon the occurrence of each adjustment or
readjustment of the Exercise Price pursuant to this Section 3, the Company, at its expense, shall
promptly compute such adjustment or readjustment of the Exercise Price in accordance with the terms
hereof and furnish to each Holder of Warrants a certificate setting forth such adjustment or
readjustment and showing in detail the facts upon which such adjustment or readjustment is based,
including a statement of (i) the consideration received or deemed to be received by the Company for
any Additional Shares of Common Stock issued or deemed to have been issued, (ii) the Exercise Price
in effect immediately prior to such adjustment or readjustment, (iii) the number of Additional
Shares of Common Stock issued or deemed to have been issued and (iv) the number of shares of Common
Stock and the amount, if any, of other securities or property that at the time would be received
upon the exercise of the Warrants. The Company shall, upon the written request at any time of any
Holder of Warrants, furnish or cause to be furnished to such Holder a like certificate setting
forth (x) all adjustments and readjustments of the Exercise Price since the Original Issue Date and
(y) the Exercise Price then in effect.

3.5 Assurances With Respect to Exercise Rights. The Company shall not, by amendment
of its Certificate of Incorporation or By-laws or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms to be observed or
performed hereunder by the Company, but shall at all times, in good faith, assist in the carrying
out of all the provisions of this Agreement and in taking of all such actions as may be necessary
or appropriate in order to protect the exercise rights of the Warrant Holder against impairment or
dilution.

4. Transfers.

4.1 Unregistered Securities. The Warrant Holder hereby acknowledges and agrees that
the Warrants and the Shares have not been registered under the Securities Act of 1933, as amended
(the “Securities Act”), and are “restricted securities” under the Securities Act inasmuch as they
are being acquired in a transaction not involving a public offering, and the Warrant Holder agrees
not to sell, pledge, distribute, offer for sale, transfer or otherwise dispose of the Warrants or
any Shares issued upon exercise of the Warrants in the absence of (a) an effective registration
statement under the Act as to the Warrants or such Shares and registration and/or qualification of
the Warrants or such Shares under any applicable Federal or state securities law then in effect or
(b) an opinion of counsel, reasonably satisfactory to the Company, that such registration and
qualification are not required.

4.2 Transferability. Subject to the provisions of Section 4.1 hereof, the rights
under this Agreement are freely transferable, in whole or in part, by the Warrant Holder, and such
transferee shall have the same rights hereunder as the Warrant Holder.

4.3 Warrant Register. The Company will maintain a register containing the names and
addresses of the Warrant Holders of the Warrants. Until any transfer of Warrants in accordance with
this Agreement is reflected in the warrant register, the Company may treat the Warrant Holder as
the absolute owner hereof for all purposes. Any Warrant Holder may change such Warrant Holder’s
address as shown on the warrant register by written notice to the Company requesting such change.

5. No Fractional Shares. Any adjustment in the number of Shares purchasable hereunder
shall be rounded to the nearest whole share.

6. Investment Representations. The Warrant Holder agrees and acknowledges that it is
acquiring the Warrants and will be acquiring the Shares for its own account and not with a view to
any resale or distribution other than in accordance with Federal and state securities laws. The
Warrant Holder is an “accredited investor” within the meaning of Rule 501(a) of Regulation D
promulgated under the Securities Act.

7. Covenants as to the Shares. The Company covenants and agrees that the shares of Common
Stock issuable upon exercise of the Warrants, will, upon issuance in accordance with the terms
hereof, be duly and validly issued and outstanding, fully paid and nonassessable, with no personal
liability attaching to the ownership thereof, and free from all taxes, liens and charges with
respect to the issuance thereof imposed by or through the Company; provided,
however, that the Company shall not be required to pay any tax that may be payable in
respect of any transfer involved in the issuance and delivery of any certificates in respect of
such shares in a name other than that of the Warrant Holder and the Company shall not be required
to issue or deliver such certificates unless or until the person(s) requesting the issuance thereof
shall have paid to the Company the amount of such tax or it shall be established to the
satisfaction of the Company that such tax has been paid. The Company further covenants and agrees
that the Company will at all times have authorized and reserved, free from preemptive rights
imposed by or through the Company, a sufficient number of shares of Common Stock to provide for the
exercise of the rights represented under this Agreement.

8. Legend. Any certificate evidencing the Shares issuable upon exercise hereof will bear a
legend indicating that such securities have not been registered under the Securities Act or under
any state securities laws and may not be sold or offered for sale in the absence of an effective
registration statement as to the securities under the Securities Act and any applicable state
securities law or an opinion of counsel reasonably satisfactory to the Company that such
registration is not required.

9. Dividends and Other Distributions. In the event that the Company shall, at any time
prior to the exercise of all Warrants, declare a dividend (other than a dividend consisting solely
of shares of Common Stock) or otherwise distribute to its stockholders any assets, properties,
rights, evidence of indebtedness, securities (other than shares of Common Stock), whether issued by
the Company or by another, or any other thing of value, the Warrant Holder shall thereafter be
entitled, in addition to the shares of Common Stock or other securities and property receivable
upon the exercise thereof, to receive, upon the exercise of such Warrants, the same property,
assets, rights, evidences of indebtedness, securities or any other thing of value that the Warrant
Holder would have been entitled to receive at the time of such dividend or distribution as if the
Warrants had been exercised immediately prior to such dividend or distribution. At the time of any
such dividend or distribution, the Company shall make (and maintain) appropriate reserves to ensure
the timely performance of the provisions of this Section 9.

10. Miscellaneous.

10.1 Waivers and Amendments. This Agreement or any provisions hereof may be changed,
waived, discharged or terminated only by a statement in writing signed by the Company and by the
Warrant Holder.

10.2 Governing Law. This Agreement shall be governed by and construed and enforced in
accordance with the laws of the State of New York.

10.3 Notices. All notices and other communications hereunder shall be in writing and
shall be deemed to have been given when delivered by hand or by facsimile transmission, when
telexed, or upon receipt when mailed by registered or certified mail (return receipt requested),
postage prepaid, to the parties at the following addresses (or at such other address for a party as
shall be specified by like notice):

(i) If to the Company:

The Immune Response Corporation

5931 Darwin Court

Carlsbad, CA 92008

Attention: President

Facsimile: (760) 431-8636

With a copy (which copy shall not constitute notice) to:

Heller Ehrman LLP

4350 La Jolla Village Drive, 7th Floor

San Diego, CA 92122

Attention: Hayden Trubitt, Esq.

Facsimile: (858) 587-5903

(ii) If to the Warrant Holder:

Cheshire Associates LLC

535 Madison Avenue

New York, NY 10022

Attention: Kevin Kimberlin and Bruno Lerer, Esq.

Facsimile: (212) 486-7392

With a copy (which copy shall not constitute notice) to:

Kirkpatrick & Lockhart LLP

1251 Avenue of the Americas, 45th Floor

New York, NY 10020-1104

Attention: Stephen R. Connoni, Esq./Sandip Kakar, Esq.

Facsimile: (212) 536-3901

10.4 Headings. The headings in this Agreement are for convenience of reference only,
and shall not limit or otherwise affect the terms hereof.

10.5 Closing of Books. The Company will at no time close its transfer books against
the transfer of any Shares issued or issuable upon the exercise of the Warrants in a manner that
interferes with the timely exercise of the Warrants.

10.6 No Rights or Liabilities as a Stockholder. This Agreement shall not entitle the
Warrant Holder hereof to any voting rights or other rights as a stockholder of the Company with
respect to the Shares prior to the exercise of the Warrants. No provision of this Agreement, in the
absence of affirmative action by the Warrant Holder to purchase the Shares, and no mere enumeration
herein of the rights or privileges of the Warrant Holder, shall give rise to any liability of such
Holder for the Exercise Price or as a stockholder of the Company, whether such liability is
asserted by the Company or by creditors of the Company.

10.7 Successors. All the covenants and provisions of this Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and permitted
assigns and transferees.

10.8 Severability. If any provision of this Agreement shall be held to be invalid and
unenforceable, such invalidity or unenforceability shall not affect any other provision of this
Agreement.

IN WITNESS WHEREOF, the undersigned have caused this Warrant Agreement to be executed as of
the date first written above.

THE IMMUNE RESPONSE CORPORATION

By:

Name:

Title:

CHESHIRE ASSOCIATES LLC

By:

Name:

Title:

1

EXHIBIT A

NOTICE OF EXERCISE

(To be signed only on exercise of any of the Warrants)

Dated:     

To: The Immune Response Corporation

The undersigned, pursuant to the provisions set forth in the attached Warrant Agreement,
hereby irrevocably elects to (check one of the following):

[_] purchase      shares of Common Stock covered by such Warrant Agreement and
herewith makes a cash payment of $     , representing the full purchase price for such
shares at the price per share provided for in such Warrant Agreement.

[_] purchase      shares of Common Stock covered by such Warrant Agreement and
herewith delivers      shares of Common Stock having a Fair Market Value (as defined in such
Warrant Agreement) as of the last trading day preceding the date hereof, of $     , representing
the full purchase price for such shares at the price per share provided for in such Warrant
Agreement.

[_] acquire in a cashless exercise      shares of Common Stock pursuant to the terms of
Section 2.1 of such Warrant Agreement.

Please issue a certificate or certificates representing such shares of Common Stock in the
name of the undersigned or in such other name as is specified below.

Signature:     

Name (print):     

Title (if applicable):     

Company (if applicable):     

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]